Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Jacinth Joseph, MD, Vanessa Wookey, MD, Brion Randolph, MD, Jason C. Chandler, MD, Dennis Marjoncu, PharmD, BCOP, Kori Holman, PharmD, Deniscer Peeler, LPN, Michelle Armstrong, NP, Yasser Khaled, MD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-143049

Published: 2020

Journal Articles

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Poojitha Valasareddy, MD, Arnel Pallera, MD, Robert Johnson, MD, Deniscer Peeler, LPN, Jason C. Chandler, MD, Joel Gradowski, MD

Blood (2019) 134 (Supplement_1): 5676.

https://doi.org/10.1182/blood-2019-131954

Published: 2019

Journal Articles

Improved Relapse Rate, T Cell Recovery and Engraftment in High Risk Hematological Malignancies with Enhanced Lympho-Depletion Prior to T-Cell Replete Peripheral Blood Haploidentical (HID) Hematopoietic Stem Cell Transplantation (HCT)

Yasser Khaled, MD, Joshua Boss, RN, OCN, BMTCN, Joel Gradowski, MD, Robert Bradley, MD, Jason C. Chandler, MD

Blood (2018) 132 (Supplement 1): 2117.

https://doi.org/10.1182/blood-2018-99-115290

Published: 2018

Journal Articles

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Yasser Khaled, MD, Jason C. Chandler, MD, Joshua Boss, RN, OCN, Arnel Pallera, MD, Michael G. Martin, MD, Robert Bradley, MD, Robert Johnson, MD

Blood (2017) 130 (Supplement 1): 1934.

https://doi.org/10.1182/blood.V130.Suppl_1.1934.1934

Published: 2017

Journal Articles

Pre-Transplant Low Dose Cyclophosphamide Enhances Engraftment and Immune Reconstitution in Haploidentical Hematopoietic Stem Cell Transplant (HCT) Recipients Receiving Total Body Radiation (TBI) Free Reduced Intensity Conditioning with Post- Transplant Cyclophosphamide (PTCY)

Yasser Khaled, MD, George Yaghmour, MD, Christy R Parks, FNP, Deborah Lamontagne, MLS(ASCP)CM, Joshua Boss, RN, Diwura Owolabi, PharmD, BCOP, Sallyanne C. Fossey, PhD, Lisa Murphy, MT(ASCP), Robert Bradley, MD

Blood (2016) 128 (22): 3431.

https://doi.org/10.1182/blood.V128.22.3431.3431

Published: 2016

Journal Articles

Thymoglobulin Does Not Impact Relapse or Survival after Matched Unrelated Transplantation for AML/MDS Compared to Matched Related Donor Transplantation without Thymoglobulin Use

Yasser Khaled, MD, Rushang D. Patel, MDPhD, Shahram Mori, MD PhD, Wesam B. Ahmed, MD PhD, Melhem Solh, MD

Blood (2015) 126 (23): 5477.

https://doi.org/10.1182/blood.V126.23.5477.5477

Published: 2015

Journal Articles

Effect of Graft and Early Posttransplantation Invariant Natural Killer T Cells on Disease Relapse Post Allogeneic Hematopoeitic Cell Transplantation

Sauvi chang-Fong, Kristin Rathmann, Julie Pepe, Yasser Khaled, MD, Alicja J Copik, PhD, Jeremiah Oyer, Melhem M. Solh, MD

Blood (2014) 124 (21): 3823.

https://doi.org/10.1182/blood.V124.21.3823.3823

Published: 2014

Journal Articles

Method of Mobilization: Implication on Cell Subsets in the Graft and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation (AHCT)

Melhem M. Solh, MD, Rathmann Kristin, MS, Sauvi chang-Fong, Jeremiah Oyer, Wesam B. Ahmed, MD PhD, Alicja J Copik, PhD, Yasser Khaled, MD

Blood (2014) 124 (21): 1132.

https://doi.org/10.1182/blood.V124.21.1132.1132

Published: 2014

Journal Articles

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid Leukemia/ Myelodysplastic Syndrome Conditioned With Intravenous Busulfan and Fludarabine

Yasser Khaled, MD, Megan Smith, Tori Smith, Jason Balls, Abraham Matar, Deborah Lamontagne, Roy M. Ambinder, MD, Ahmed Zakari, MD, Melhem M. Solh, MD

Blood (2013) 122 (21): 5453.

https://doi.org/10.1182/blood.V122.21.5453.5453

Published: 2013

Journal Articles

Generation Of Clinical Grade, Highly Cytotoxic NK Cells Using Feeder Cell Free, Particle-Based Technology

Jerremiah Oyer, Igarashi Y Robert, Ph.D., Colosimo Dominic, Melhem M. Solh, MD, Yasser Khaled, MD, Alicja J Copik, PhD

Blood (2013) 122 (21): 4503.

https://doi.org/10.1182/blood.V122.21.4503.4503

Published: 2013

Journal Articles

Guilain-Barre’ Syndrome (GBS) Post Adult Cord Blood Transplantation In a Patient With Chronic Lymphocytic Leukemia (CLL)

Melhem M. Solh, MD, Tori Smith, Jason Balls, Megan Smith, Yasser Khaled, MD

Blood (2013) 122 (21): 5497.

https://doi.org/10.1182/blood.V122.21.5497.5497

Published: 2013

Journal Articles

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) For Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Following Intravenous Busulfan/Fludarabine Based Conditioning: Outcomes and Monocyte Chemo-Attractant Protein -1( MCP-1) As a Predictive Marker Of Relapse

Abraham Matar, BS, Melhem M. Solh, MD, Alicja J Copik, PhD, Sally Litherland, PhD, Alvin oliverasAlmodovar, Kristin Rathmann, Yasser Khaled, MD

Blood (2013) 122 (21): 3325.

https://doi.org/10.1182/blood.V122.21.3325.3325

Published: 2013

Journal Articles

Effect Of Plerixafor Mobilization On Immune Reconstitution Post High Dose Chemotherapy and Autologous Stem Cell Transplantation

Melhem M. Solh, MD, Tori Smith, Yasser Khaled, MD, Alicja Copik, PhD

Blood (2013) 122 (21): 2031.

https://doi.org/10.1182/blood.V122.21.2031.2031

Published: 2013

Journal Articles

Leukocytosis Post Engraftment Is Associated with Increased Mortality Among Adult Allogeneic Hematopoietic Cell Transplant (HCT) Reciepients

Melhem M. Solh, MD, Yasser Khaled, MD

Blood (2012) 120 (21): 4536.

https://doi.org/10.1182/blood.V120.21.4536.4536

Published: 2012

Journal Articles

Plasma Cell CD20 Expression After Autologous Stem Cell Transplantation in Multiple Myeloma: Primary Aberrant Expression or Receptor up-Regulation

Yasser Khaled, MD, Melhem M. Solh, MD, David Ward, Chung-Che Chang, MD, PhD

Blood (2012) 120 (21): 4538.

https://doi.org/10.1182/blood.V120.21.4538.4538

Published: 2012

Journal Articles

Physician's Experience and Continuity of Care May Result in Superior Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematological Malignancies with Standard Conditioning Regimens and GVHD Prophylaxis

Yasser Khaled, MD, Melhem M. Solh, MD

Blood (2012) 120 (21): 4715.

https://doi.org/10.1182/blood.V120.21.4715.4715

Published: 2012

Journal Articles

The Impact of Continuity of Care On Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation; Improved Overall Survival in the Absence of Severe Graft Vs. Host Disease

Yasser Khaled, MD, Melhem M. Solh, MD, Robert B. Reynolds, MD, Carlos Alemany, MD, Raul Castillo, MD, Sarah George, MD, Linda Lukman, MD, Ahmed Zakari, MD, Lee Zehngebot, MD

Blood (2012) 120 (21): 4521.

https://doi.org/10.1182/blood.V120.21.4521.4521

Published: 2012

Journal Articles

Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes.

Yasser Khaled, MD, Sung Choi, MD, David A Hanauer, MD, MS, Pavan Reddy, MD

Blood (2009) 114 (22): 3324.

https://doi.org/10.1182/blood.V114.22.3324.3324

Published: 2009

Journal Articles

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Andrzej Jakubowiak, MD, PhD, Tara Kendall, PA, Ammar Al-Zoubi, MD, Yasser Khaled, MD, Shin Mineishi, MD, Christine Brozo, Erica Campagnaro, MD, Moshe Talpaz, Mark S. Kaminski, MD

Blood (2008) 112 (11): 3713.

https://doi.org/10.1182/blood.V112.11.3713.3713

Published: 2008

Journal Articles

Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar ® ) Correlates with Response to Therapy

Andrzej J. Jakubowiak, MD, PhD, Malathi Hari, PhD, Tara Kendall, PA, Yasser Khaled, MD, Shin Mineishi, MD, Ammar Al-Zoubi, MD, Mark S. Kaminski, MD, Ivan Maillard, MD, PhD

Blood (2008) 112 (11): 5176.

https://doi.org/10.1182/blood.V112.11.5176.5176

Published: 2008

NARROW

Fresh Versus Cryopreserved Peripheral Stem Cell for Autologous Transplantation in Multiple Myeloma: An Analysis of Short-Term Outcomes

Early Immune Reconstitution after Haplo-Identical Hematopoietic Stem Cell Transplantation (HCT) with Post-Transplant Cyclophosphamide (PTCY) Does Not Improve Overall Survival Compared to Matched Unrelated Donor HCT Recipients Receiving Thymoglobulin Prophylaxis (ATG)

Improved Relapse Rate, T Cell Recovery and Engraftment in High Risk Hematological Malignancies with Enhanced Lympho-Depletion Prior to T-Cell Replete Peripheral Blood Haploidentical (HID) Hematopoietic Stem Cell Transplantation (HCT)

T-Cell Replete Peripheral Blood Haploidentical Transplant Using Immunogenic Dose of Cyclophosphamide with Fludarabine and Melphalan Results in Enhanced Cytokine Release Syndrome (CRS) with Robust Immune Recovery and Low Relapse Rates

Pre-Transplant Low Dose Cyclophosphamide Enhances Engraftment and Immune Reconstitution in Haploidentical Hematopoietic Stem Cell Transplant (HCT) Recipients Receiving Total Body Radiation (TBI) Free Reduced Intensity Conditioning with Post- Transplant Cyclophosphamide (PTCY)

Thymoglobulin Does Not Impact Relapse or Survival after Matched Unrelated Transplantation for AML/MDS Compared to Matched Related Donor Transplantation without Thymoglobulin Use

Effect of Graft and Early Posttransplantation Invariant Natural Killer T Cells on Disease Relapse Post Allogeneic Hematopoeitic Cell Transplantation

Method of Mobilization: Implication on Cell Subsets in the Graft and Immune Reconstitution Post Autologous Hematopoietic Cell Transplantation (AHCT)

Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid Leukemia/ Myelodysplastic Syndrome Conditioned With Intravenous Busulfan and Fludarabine

Generation Of Clinical Grade, Highly Cytotoxic NK Cells Using Feeder Cell Free, Particle-Based Technology

Guilain-Barre’ Syndrome (GBS) Post Adult Cord Blood Transplantation In a Patient With Chronic Lymphocytic Leukemia (CLL)

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation (HCT) For Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) Following Intravenous Busulfan/Fludarabine Based Conditioning: Outcomes and Monocyte Chemo-Attractant Protein -1( MCP-1) As a Predictive Marker Of Relapse

Effect Of Plerixafor Mobilization On Immune Reconstitution Post High Dose Chemotherapy and Autologous Stem Cell Transplantation

Leukocytosis Post Engraftment Is Associated with Increased Mortality Among Adult Allogeneic Hematopoietic Cell Transplant (HCT) Reciepients

Plasma Cell CD20 Expression After Autologous Stem Cell Transplantation in Multiple Myeloma: Primary Aberrant Expression or Receptor up-Regulation

Physician's Experience and Continuity of Care May Result in Superior Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematological Malignancies with Standard Conditioning Regimens and GVHD Prophylaxis

The Impact of Continuity of Care On Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation; Improved Overall Survival in the Absence of Severe Graft Vs. Host Disease

Nephrotic Syndrome After Allogeneic Hematopoietic Cell Transplantation: Incidence and Outcomes.

Initial Treatment with Bortezomib (Velcade ® ), Doxil ® , and Dexamethasone (VDD) Is Superior to Thalidomide and Dexamethasone (TD) as Initial Therapy Prior to Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)

Elimination of CD20-Expressing Cells in Multiple Myeloma by Iodine I-131 Tositumomab (Bexxar ® ) Correlates with Response to Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only